Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Dr. Bardwell on Cancer-Related Variables and Depression

      October 25, 2011
      By Wayne A. Bardwell, PhD, MBA
      Article

      Dr. Wayne Bardwell from UCSD Cancer Center on Cancer-Related Variables and Depression

      Wayne A. Bardwell, PhD, MBA, Associate Professor of Psychiatry, director, Patient & Family Support Service, Doris Howell Service Moores, University of California, San Diego, Cancer Center, discusses his research into the connection between objective cancer-related variables and depression symptoms in breast cancer patients.

      The depression symptoms analysis was completed as part of the Women's Healthy Eating and Living (WHEL) study that examined the effects of dietary intervention on 3088 women following the completion of treatment for early-stage breast cancer. Data was collected before and after the introduction of the dietary intervention and tested against 27 potential risk factors that predict depression. Each factor was measured using various instruments that were selected based on social cognitive theory.

      The results of the study were counterintuitive. Objective cancer-related factors, such as intensity of treatment and length of time from diagnosis, as well as health-related factors, such as side effects and physical activity, did not play a role in developing depression. The lead cause of depression stemmed from psychosocial factors such as insomnia, support groups, and being comfortable expressing feelings. These psychosocial issues are very similar to the cause of depression in the general population.

      The trial concluded that depressive symptoms are not associated with objective cancer-related factors but are connected to subjective psychosocial variables.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman with brown hair and bangs
      Photo of a man wearing a suit in front of an Oncology Nursing News backdrop
      Related Content

      Graphic depicting a nurse with a cell strucutre behind. Graphic by Gwendolyn Salas, MJH Life Sciences, with AI

      Structure to Safety: A Nurse's Guide to Safe ADC Care

      Ellen Rice Tichich, MFA, MSN, RN, NPD-BC
      September 16th 2025
      Article

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      September 16th 2025
      Podcast

      Line illustration of a breast on a yellow background

      CDK4/6 Inhibitors: How to Tailor Treatment Choices by AEs

      Bridget Hoyt
      September 16th 2025
      Article

      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      September 16th 2025
      Podcast

      Icon of a breast with various clinicians using medical equipment

      Personalizing CDK4/6 Inhibitor Care to Reduce Adverse Events

      Bridget Hoyt
      September 16th 2025
      Article

      Image of a person with a breast tumor

      Making Breast Cancer Treatment Decisions After Endocrine Therapy

      Bridget Hoyt
      September 16th 2025
      Article
      Related Content

      Graphic depicting a nurse with a cell strucutre behind. Graphic by Gwendolyn Salas, MJH Life Sciences, with AI

      Structure to Safety: A Nurse's Guide to Safe ADC Care

      Ellen Rice Tichich, MFA, MSN, RN, NPD-BC
      September 16th 2025
      Article

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      September 16th 2025
      Podcast

      Line illustration of a breast on a yellow background

      CDK4/6 Inhibitors: How to Tailor Treatment Choices by AEs

      Bridget Hoyt
      September 16th 2025
      Article

      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      September 16th 2025
      Podcast

      Icon of a breast with various clinicians using medical equipment

      Personalizing CDK4/6 Inhibitor Care to Reduce Adverse Events

      Bridget Hoyt
      September 16th 2025
      Article

      Image of a person with a breast tumor

      Making Breast Cancer Treatment Decisions After Endocrine Therapy

      Bridget Hoyt
      September 16th 2025
      Article

      Latest Conference Coverage

      Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care

      Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC

      Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs

      Safety Management With Amivantamab Plus Lazertinib in NSCLC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      259 Prospect Plains Rd, Bldg H,
      Monroe, NJ 08831

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.